Organogenesis Holdings Inc. (ORGO) Stock

Organogenesis Holdings Inc. (ORGO) is a Healthcare stock trading at $2.43 (as of 2026-06-18), with a market capitalization of $330.69M and a trailing P/E of -19.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Valuation — source: SEC EDGAR (first-party)
Price$2.43
Market Cap$330.69M
P/E Ratio-19.5
EV / EBITDA11.3
Price / Book1.23
Price / Sales0.58
DCF Value (model)$-2.50
DCF Upside vs Price-202.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$564.17M
Net Margin6.6%
Return on Equity1.1%
Current Ratio3.53
Revenue Growth (YoY)17.0%
EPS Growth (YoY)-1700.0%
FCF Growth (YoY)-685.7%
Financial Health — source: SEC EDGAR
Altman Z-Score2.33 (grey)
Valuation vs Sector & Industry
Stock P/E-19.5
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-193.4%
vs Industry-214.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMORGAN STANLEY ($27.53M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOGary S. Gillheeney
Employees869
CountryUS
IPO Date2017-01-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Invivyd, Inc. (IVVD)
  • Lyell Immunopharma, Inc. (LYEL)
  • Emergent BioSolutions Inc. (EBS)
  • MeiraGTx Holdings plc (MGTX)
  • Gyre Therapeutics, Inc. (GYRE)
  • Prime Medicine, Inc. (PRME)
  • Cullinan Therapeutics, Inc. (CGEM)
  • SELLAS Life Sciences Group, Inc. (SLS)
ORGO earnings history · ORGO institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.